Sodium Ferric Gluconate Complex: A Comprehensive Pharmacological and Clinical Review

I. Introduction to Sodium Ferric Gluconate Complex

Sodium ferric gluconate complex is an intravenously administered iron replacement product. Its primary, Food and Drug Administration (FDA)-approved indication is for the treatment of iron deficiency anemia (IDA) in adult patients and in pediatric patients aged 6 years and older who have chronic kidney disease (CKD) and are undergoing hemodialysis, specifically when they are also receiving supplemental epoetin therapy.[1] This precise indication underscores its development for a patient population with complex anemia etiologies and high iron demands. It serves as a critical parenteral iron source when oral iron supplementation is insufficient, poorly tolerated, or ineffective, a common scenario in the CKD-HD population.[1] The medication is marketed under various brand names, most notably Ferrlecit® and Nulecit™.[2]

The specificity of the FDA indication, linking the use of sodium ferric gluconate complex with concomitant epoetin therapy in CKD-HD patients, points to a targeted therapeutic strategy. Epoetin, an erythropoiesis-stimulating agent (ESA), triggers the bone marrow to produce more red blood cells. Iron is an indispensable component of hemoglobin, the oxygen-carrying molecule within these cells. Consequently, increased erythropoiesis due to epoetin leads to a substantially increased physiological demand for iron. Patients with CKD, particularly those on hemodialysis, often suffer from functional or absolute iron deficiency due to a combination of factors including poor oral iron absorption, dietary restrictions, inflammation-mediated iron sequestration (functional deficiency), and blood loss during the dialysis procedure itself. Therefore, providing epoetin without ensuring an adequate and readily available supply of iron would render the epoetin therapy suboptimal or ineffective. Sodium ferric gluconate complex is designed to meet this heightened, epoetin-induced iron demand that oral iron supplements often cannot satisfy, making the combination a synergistic approach to managing anemia in this challenging patient group.[1]

Furthermore, the inclusion of a pediatric indication for children aged 6 years and older is significant. It suggests that sufficient safety and efficacy data have been established for this younger, vulnerable demographic within the CKD-HD context, which is not universally the case for all intravenous iron preparations. Pediatric drug development, particularly for specialized conditions like IDA in CKD-HD, often requires dedicated studies due to differences in physiology, pharmacokinetics, and safety considerations compared to adults. The existence of specific pediatric dosing guidelines, such as 1.5 mg/kg as detailed in the Nulecit® label [9], and efficacy data from dedicated pediatric studies (e.g., Study C in the Nulecit® label [9]), indicates that the drug has undergone evaluation in this population. This distinguishes it from IV iron products that may lack robust pediatric data or specific approvals for this age group and indication, thereby offering a degree of confidence for its use by clinicians managing IDA in this pediatric subpopulation.[1]

II. Chemical Profile and Formulation

A. Nomenclature and Identifiers

Sodium ferric gluconate complex is the established name for this iron preparation [User Query]. It is identified by the DrugBank ID DB09517 and the Chemical Abstracts Service (CAS) Number 34089-81-1.[1] An older, deprecated CAS number is 33135-40-9.[1] While classified by DrugBank as a "Small Molecule," it is, in fact, a macromolecular complex.[3]

The International Union of Pure and Applied Chemistry (IUPAC) name for the complex is sodium;(2R,3R,4S,5S,6R)-2-oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate.[1] This detailed nomenclature reflects the intricate chelation of ferric iron with gluconate ligands and its association with sucrose molecules and sodium ions. Medical Subject Headings (MeSH) entry terms include "ferric gluconate," "Ferrlecit," "sodium ferrigluconate," and "sodium iron(III)gluconate," among others, reflecting its various terminologies in scientific and medical literature.[1]

B. Structural Characteristics and Molecular Properties

Sodium ferric gluconate complex is a stable macromolecular entity. The core structure consists of iron (III) oxide hydrate, where the iron is in the trivalent (ferric, Fe³⁺) oxidation state. This iron core is directly bonded to sucrose molecules and features a chelating gluconate function.[1] The molar ratio of iron to gluconate within the complex is two iron molecules to one gluconate molecule.[1]

The apparent molecular weight of the complex, as determined by gel chromatography, ranges from 289,000 to 440,000 Daltons.[1] This large size is characteristic of colloidal intravenous iron preparations and significantly influences its pharmacokinetic behavior, particularly its mechanism of clearance and iron release. At alkaline pH, the complex is negatively charged, which can affect its interaction with biological membranes and proteins.[1] The structural formula is considered to be [NaFe₂O₃(C₆H₁₁O₇)(C₁₂H₂₂O₁₁)₅]n≈200, suggesting a polymeric structure with approximately 200 repeating units.[9] Solutions of sodium ferric gluconate complex exhibit a characteristic deep red color, which is indicative of the ferric oxide linkages within the complex structure.[9]

C. Pharmaceutical Formulation and Excipients

Sodium ferric gluconate complex is supplied as an injection, typically in single-dose vials, for intravenous administration.[6] Each 5 mL vial generally contains 62.5 mg of elemental iron, resulting in a concentration of 12.5 mg of elemental iron per mL.[6] This standardized concentration is essential for accurate dosage calculations.

The formulation is an alkaline aqueous solution containing approximately 20% sucrose w/v (equivalent to 195 mg/mL) in water for injection.[1] Sucrose plays a crucial role as a stabilizer for the iron complex, preventing premature iron release, aggregation of the complex, and maintaining its structural integrity. The pH of the solution is alkaline, typically maintained within the range of 7.7 to 9.7, which is important for the stability and negative charge of the complex.[9]

Many, if not all, formulations of sodium ferric gluconate complex (such as Ferrlecit® and Nulecit™) contain benzyl alcohol at a concentration of 9 mg/mL as an inactive ingredient, which typically serves as a preservative.[1] The presence of benzyl alcohol has significant clinical implications, particularly for neonates and during pregnancy or lactation, due to potential toxicity.

While specific osmolarity values for Ferrlecit® or Nulecit™ are not explicitly detailed in the provided information, it is known that other intravenous iron preparations, such as ferric carboxymaltose, aim for physiologic osmolarity to enhance tolerability.[15] However, the substantial concentration of sucrose (approximately 20% w/v) in sodium ferric gluconate complex formulations inherently makes the solution hyperosmolar relative to physiological fluids. This hyperosmolarity could potentially contribute to infusion site reactions or discomfort if the drug is administered too rapidly or in an undiluted form without adherence to recommended rates.

The macromolecular structure, with its large molecular weight and encompassing carbohydrate shell (composed of sucrose and gluconate), is fundamental to the drug's overall safety and efficacy profile. This complex architecture is designed to prevent the rapid dissociation and release of large quantities of free iron into the bloodstream. Free iron is highly reactive and can catalyze the formation of deleterious reactive oxygen species, leading to cellular toxicity. The carbohydrate shell not only stabilizes the iron core but also dictates the pharmacokinetic behavior of the complex, particularly its targeted uptake by the reticuloendothelial system (RES), which then facilitates a controlled release of iron.[1] This controlled delivery is a key feature distinguishing such complexes from simpler iron salts and is crucial for minimizing acute toxicity while ensuring iron availability for physiological needs.

The inclusion of benzyl alcohol as a preservative in many formulations is a critical consideration. Benzyl alcohol has been associated with a fatal "gasping syndrome" in premature infants and neonates. Consequently, product labeling carries specific warnings regarding its use in these populations.[6] Information from resources like the Drugs and Lactation Database (LactMed) indicates that benzyl alcohol can be excreted into breast milk, leading to recommendations that alternative IV iron preparations (either lacking benzyl alcohol or with more established safety data in lactation) might be preferable for breastfeeding mothers.[1] Similarly, pregnancy warnings highlight the potential risks associated with benzyl alcohol, advising use only if clearly necessary.[6] This makes the awareness and consideration of excipients paramount for clinicians when selecting an IV iron product, especially for vulnerable patient groups.

Table 1: Physicochemical and Formulation Properties of Sodium Ferric Gluconate Complex

Property	Value/Description	Reference(s)
IUPAC Name	sodium;(2R,3R,4S,5S,6R)-2-oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate	1
Common Synonyms	Ferrlecit®, Nulecit™, Sodium Iron(III) Gluconate	1
CAS Number	34089-81-1	1
DrugBank ID	DB09517	3
Representative Structural Formula	[NaFe₂O₃(C₆H₁₁O₇)(C₁₂H₂₂O₁₁)₅]n≈200	9
Apparent Molecular Weight	289,000 – 440,000 Daltons	1
Physical Appearance of Solution	Deep red color	9
Elemental Iron Content	12.5 mg/mL (typically 62.5 mg per 5 mL vial)	6
Sucrose Concentration	Approximately 20% w/v (195 mg/mL)	1
Benzyl Alcohol Content (in some formulations)	9 mg/mL	1
pH of Solution	7.7 – 9.7 (alkaline)	9

III. Mechanism of Action and Pharmacodynamics

Sodium ferric gluconate complex functions as an iron replacement product, specifically formulated to replenish the total body iron content in individuals suffering from iron deficiency.[1] Iron is an element of paramount physiological importance. It is indispensable for the synthesis of hemoglobin, the protein within red blood cells responsible for oxygen transport from the lungs to all body tissues. Additionally, iron is a crucial component of myoglobin, which facilitates oxygen storage in muscle cells, and it serves as a cofactor for numerous enzymes involved in vital metabolic processes, including oxidative metabolism and the biosynthesis of deoxyribonucleotides by ribonucleotide reductase (RNR), an enzyme essential for DNA synthesis and repair.[1]

Following intravenous administration, the sodium ferric gluconate complex is not immediately bioavailable as free iron. Instead, the macromolecular complex is primarily taken up from the circulation by macrophages of the reticuloendothelial system (RES). These specialized phagocytic cells are predominantly located in the liver, spleen, and bone marrow. The uptake mechanism involves endocytosis of the complex.[3] Once internalized within the macrophages, the complex is trafficked to endosomes. These endosomes subsequently fuse with lysosomes, which are organelles containing hydrolytic enzymes and maintaining an acidic internal environment (low pH). This acidic milieu within the lysosome facilitates the cleavage of iron from its surrounding carbohydrate shell (sucrose and gluconate ligands).[3]

Once liberated from the complex, the iron follows established physiological pathways. It can be incorporated into ferritin, the primary intracellular iron storage protein, thereby replenishing tissue iron stores within the macrophages themselves or other cells. Alternatively, the released iron can be exported from the macrophage and bind to transferrin, the main iron transport protein in the plasma. Transferrin then delivers the iron to sites of active utilization, most notably to erythroid precursor cells in the bone marrow, where it is incorporated into heme and subsequently into hemoglobin during erythropoiesis.[1]

The principal pharmacodynamic outcome of administering sodium ferric gluconate complex is an increase in the systemic iron supply that is readily available for erythropoiesis. In patients with iron deficiency anemia, particularly those with CKD on hemodialysis whose erythropoiesis is concurrently stimulated by exogenous epoetin therapy, this enhanced iron availability supports an increased rate of red blood cell production. This, in turn, leads to improvements in hemoglobin levels, hematocrit, and other iron indices such as transferrin saturation (TSAT) and serum ferritin levels, reflecting both improved iron transport and repleted stores.[3]

The mechanism involving RES uptake and subsequent lysosomal processing represents a sophisticated physiological strategy for iron delivery. This pathway mirrors the body's natural process for recycling iron from senescent red blood cells. By utilizing this endogenous machinery, the drug ensures a controlled, cell-mediated release of iron. This is critically important because it minimizes the exposure of the circulation to large boluses of free, unbound iron, which can be toxic due to its capacity to catalyze the formation of harmful reactive oxygen species. This controlled release distinguishes it from the direct absorption of oral iron salts (if they were given IV in large amounts) and is a key design feature aimed at mitigating the toxicity associated with parenteral iron administration while ensuring efficient delivery to where it is needed.

The effectiveness of sodium ferric gluconate complex in treating IDA in CKD patients on hemodialysis is multi-faceted. These patients often have compromised oral iron absorption, increased iron losses due to the dialysis procedure, and an inflammatory state that can impair iron mobilization from stores (functional iron deficiency). Oral iron is frequently insufficient or poorly tolerated in this population. Sodium ferric gluconate complex bypasses these gastrointestinal absorption issues and delivers iron directly into the RES, a central player in iron homeostasis and delivery to erythropoietic tissues. This ensures that the provided iron is in a bioavailable form, ready for efficient utilization in hemoglobin synthesis, especially when erythropoiesis is pharmacologically driven by concomitant epoetin therapy.

IV. Pharmacokinetics

A. Administration and Distribution

Sodium ferric gluconate complex is administered exclusively via the intravenous (IV) route. Depending on the clinical setting and patient needs, it can be given as a diluted infusion over a specified period or as a slow undiluted injection.[2]

Following IV administration, the initial volume of distribution for the drug-bound iron, denoted as VFerr, is approximately 6 Liters.[10] This volume corresponds well with the calculated plasma or blood volume, indicating that the initial distribution of the intact complex is largely confined to the vascular compartment. Studies cited in product labeling suggest that VFerr does not vary significantly with the dosage administered or the rate of administration.[10]

The iron within the complex, once released through processing by the reticuloendothelial system, binds with high affinity to transferrin. Transferrin is the body's physiological iron transport protein, responsible for delivering iron to cells throughout the body, particularly to the bone marrow for hemoglobin synthesis. Iron not immediately utilized is stored primarily in the liver, spleen, and bone marrow within the protein ferritin.[1] The intact sodium ferric gluconate complex itself is not subject to protein binding in the conventional sense; rather, its fate is determined by cellular uptake.

B. Metabolism and Iron Utilization

Sodium ferric gluconate complex does not undergo "metabolism" in the typical pharmacological sense involving enzymatic biotransformation by systems like the cytochrome P450 enzymes. Instead, its processing is a physiological mechanism. The intact macromolecular complex is cleared from the circulation primarily through uptake by the cells of the reticuloendothelial system (RES), particularly macrophages located in the liver, spleen, and bone marrow.[3]

Within these RES cells, the iron core is dissociated from its carbohydrate shell (composed of gluconate and sucrose molecules). This liberation of iron occurs within the acidic environment of lysosomes following endocytosis of the complex.[3] A significant portion of the iron administered as sodium ferric gluconate complex is subsequently made available to transferrin. Clinical pharmacokinetic data indicate that approximately 80% of the drug-bound iron is delivered to transferrin, in the form of a mononuclear ionic iron species, within 24 hours of administration. This efficient transfer to transferrin was observed consistently across various dosage regimens studied [10] and is a critical step for the subsequent physiological utilization of the iron for erythropoiesis and other iron-dependent processes.

C. Elimination

The terminal elimination half-life (t1/2​) for the circulating drug-bound iron complex is relatively short, averaging approximately 1 hour in adult patients. This pharmacokinetic parameter has been observed to vary somewhat with the dose administered; for instance, studies reported values ranging from 0.85 hours for a 62.5 mg dose to 1.45 hours for a 125 mg dose. However, the rate of administration did not appear to significantly influence this half-life.[10] In pediatric patients (ages 6 to 15 years), the mean terminal elimination half-life was reported as 2.0 hours following a 1.5 mg/kg dose and 2.5 hours following a 3.0 mg/kg dose.[10]

The total clearance (CL) of Ferrlecit®-bound iron from the plasma ranged from 3.02 to 5.35 L/h. Similar to the elimination half-life, total clearance did not show significant variation with changes in the rate of administration.[10]

Iron, as an essential mineral, is not readily eliminated from the body through typical excretory pathways such as renal or biliary excretion in the same manner as many xenobiotic drugs.[9] The body tightly regulates iron balance primarily by controlling its absorption from the gastrointestinal tract. Since sodium ferric gluconate complex is administered intravenously, this absorptive regulation is bypassed. Studies in renally competent individuals have indicated that urinary excretion of iron derived from the complex is clinically insignificant.[10]

A crucial pharmacokinetic characteristic, especially for its indicated use, is its dialyzability. The sodium ferric gluconate complex itself is not significantly removed by hemodialysis. In vitro experiments using dialysis membranes with pore sizes of 12,000 to 14,000 Daltons demonstrated that less than 1% of the iron from Ferrlecit® was dialyzed over a period of up to 270 minutes.[10] Product labeling for Nulecit™ also explicitly states that the iron complex is not dialyzable.[9]

The combination of a relatively short circulating half-life of the iron complex (approximately 1 hour) with the efficient transfer of about 80% of its iron payload to transferrin within 24 hours points to a rapid and effective processing mechanism. This ensures that the administered iron does not linger in its complexed form in the circulation for excessively long durations. Instead, it is quickly taken up by the RES and its iron content is made available to the body's physiological iron transport and utilization systems. Such a pharmacokinetic profile is advantageous for patients with IDA who require prompt iron repletion to support erythropoiesis.

The non-dialyzability of the sodium ferric gluconate complex is a fundamental pharmacokinetic property that underpins its suitability and efficacy in patients undergoing hemodialysis. This characteristic ensures that the therapeutically administered dose of iron is retained by the patient and not inadvertently and significantly removed during the concurrent dialysis procedure. This retention maximizes the therapeutic benefit and allows for more predictable patient responses to the iron therapy. If the complex were dialyzable, a substantial portion of the administered dose could be lost, thereby reducing its efficacy and necessitating adjustments in dosing strategies.

Table 2: Summary of Key Pharmacokinetic Parameters for Sodium Ferric Gluconate Complex

Parameter	Value/Description	Reference(s)
Route of Administration	Intravenous (diluted infusion or slow undiluted injection)	6
Initial Volume of Distribution (VFerr)	Approx. 6 Liters (corresponds to blood/plasma volume)	10
Terminal Elimination Half-life (Adults)	Approx. 1 hour (range 0.85 h for 62.5 mg to 1.45 h for 125 mg)	10
Terminal Elimination Half-life (Pediatrics)	2.0 hours (1.5 mg/kg dose); 2.5 hours (3.0 mg/kg dose)	10
Total Clearance (CL)	3.02 to 5.35 L/h	10
Primary Mechanism of Clearance/Processing	Uptake by Reticuloendothelial System (RES) macrophages, followed by intracellular iron release	3
Dialyzability	Not significantly dialyzable (<1% in vitro; product labels state not dialyzable)	9
Time to Transfer ~80% Iron to Transferrin	Within 24 hours post-administration	10

V. Clinical Applications

A. Approved Therapeutic Indications (FDA, EMA)

The Food and Drug Administration (FDA) has approved sodium ferric gluconate complex, under brand names such as Ferrlecit® and Nulecit™, for a specific therapeutic use: the treatment of iron deficiency anemia in adult patients and in pediatric patients aged 6 years and older who have chronic kidney disease (CKD) and are receiving maintenance hemodialysis, and who are concurrently receiving supplemental epoetin therapy.[1] This indication is precise, highlighting its role in a patient population characterized by high iron requirements due to ongoing blood loss during dialysis, impaired oral iron absorption, inflammatory blockade of iron mobilization, and the increased erythropoietic drive stimulated by ESAs.

In Europe, the regulatory perspective on intravenous iron preparations, including sodium ferric gluconate, is somewhat broader. Following a comprehensive review (Article 31 referral) by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which concluded in June 2013 and was subsequently endorsed by the European Commission in September 2013, intravenous iron products are considered valuable alternatives when oral iron supplements are ineffective, cannot be used (e.g., due to intolerance), or when there is a clinical need for rapid iron delivery. This applies particularly to patients receiving dialysis for kidney failure, patients in the peri-operative period (before and after surgery), or in cases of malabsorption syndromes affecting the gut.[8] The EMA's guidance focuses more on the general clinical scenarios necessitating IV iron, rather than being strictly tied to concomitant epoetin use as in the FDA label.

B. Overview of Off-Label Considerations and Use Guidelines

While the FDA-approved indication is specific, clinical practice and payer policies often recognize the utility of sodium ferric gluconate complex in broader contexts of iron deficiency anemia where IV iron is warranted. Clinical policy documents from various healthcare payers, such as Louisiana Healthcare Connections (policy LA.PHAR.166) and NH Healthy Families, delineate criteria for the use of ferric gluconate that may encompass situations beyond the strict confines of the FDA label.[4]

For instance, policy LA.PHAR.166 [4] outlines criteria for "Iron Deficiency Anemia without Chronic Kidney Disease (off-label)" if oral iron therapy is deemed not optimal. Conditions rendering oral iron suboptimal include:

• Transferrin saturation (TSAT) < 12%
• Hemoglobin (Hgb) < 7 g/dL
• Symptomatic anemia
• Severe or ongoing blood loss
• Documented intolerance to oral iron preparations
• Inability to achieve therapeutic iron targets with oral iron
• Presence of co-existing conditions (e.g., inflammatory bowel disease, malabsorption syndromes) that may render the patient refractory to, or unsuitable for, oral iron therapy.

Medical information resources like Medscape generally reiterate the FDA-approved indication but may also acknowledge its broader application in treating "iron-poor" blood (anemia) in patients with long-term kidney disease.[16] Similarly, Drugs.com, while primarily detailing the FDA-approved use, notes that the drug "may also be used for purposes not listed in this medication guide".[17]

The divergence between the highly specific FDA label and the more encompassing EMA guidance, alongside payer-defined off-label use criteria, suggests a wider clinical applicability for sodium ferric gluconate complex than its narrow FDA approval might initially imply. Although its pivotal clinical trials were focused on the CKD-HD population receiving epoetin, its fundamental characteristics as an effective and relatively safe parenteral iron source make it a therapeutic option in other IDA scenarios where oral iron administration has failed or is contraindicated. The existence of these detailed off-label criteria within payer policies often reflects a pragmatic clinical approach, acknowledging an evidence base or strong clinical consensus that supports its use in these broader patient populations based on evolving medical understanding and patient needs.

The consistent inclusion of "supplemental epoetin therapy" within the FDA indication strongly emphasizes that the primary approved role of sodium ferric gluconate complex is to fuel ESA-driven erythropoiesis. ESAs pharmacologically stimulate the bone marrow to produce red blood cells, a process that is heavily dependent on an adequate and continuous supply of iron for hemoglobin synthesis. In the absence of such ESA stimulation, the body's demand for iron is typically lower. Consequently, the risk-benefit assessment for administering IV iron, particularly this specific agent as per its FDA label, might shift towards other iron management strategies or different IV iron products that possess broader initial indications not tied to ESA use. The off-label use policies for non-CKD IDA, for example, do not typically stipulate concomitant epoetin therapy, further supporting this distinction in primary therapeutic rationale.[4]

VI. Dosage, Administration, and Reconstitution

A. Adult Dosing Regimens (for FDA-approved indication)

For adult patients with iron deficiency anemia associated with CKD and receiving hemodialysis along with supplemental epoetin therapy, the standard recommended dosage of sodium ferric gluconate complex is 10 mL, which delivers 125 mg of elemental iron, administered per dialysis session.[5]

To achieve adequate iron repletion, most adult patients will require a minimum cumulative dose of 1.0 gram of elemental iron. This total repletion dose is typically administered in divided doses of 125 mg over eight sequential dialysis treatments.[9] Following the initial repletion course, patients may continue to receive sodium ferric gluconate complex as maintenance therapy. The maintenance dose should be the lowest dose necessary to maintain target levels of hemoglobin, hematocrit, and iron storage parameters, such as serum ferritin and transferrin saturation (TSAT).[9]

It is important to note that individual doses should generally not exceed 125 mg of elemental iron per session. Clinical experience and product labeling warn that administering higher single doses may be associated with an increased incidence and/or severity of adverse events.[7] While some sources suggest a maximum of 200 mg for ferric gluconate [7], the 125 mg limit per dialysis session is more consistently cited in FDA-approved product information for Ferrlecit® and Nulecit™.

B. Pediatric Dosing Regimens (Age 6 years and older, for FDA-approved indication)

For pediatric patients aged 6 years and older who meet the same indication criteria (IDA, CKD, hemodialysis, and epoetin therapy), the recommended dosage of sodium ferric gluconate complex is weight-based. The dose is 0.12 mL/kg of body weight, which corresponds to 1.5 mg/kg of elemental iron, administered per dialysis session.[5]

A critical cap on the pediatric dose is that it should not exceed 125 mg of elemental iron per session, irrespective of the patient's weight.[6] This effectively limits the pediatric dose to the standard adult dose at the upper end.

C. Preparation and Administration Guidelines

Sodium ferric gluconate complex requires careful preparation and administration:

• Dilution for Infusion:
• Adults: The standard 125 mg (10 mL) adult dose can be diluted in 100 mL of 0.9% Sodium Chloride Injection, USP, prior to intravenous infusion.[6]
• Pediatrics: The calculated pediatric dose (1.5 mg/kg) is typically diluted in a smaller volume of 25 mL of 0.9% Sodium Chloride Injection, USP.[9]
• Rate of Infusion (Diluted Product): When administered as a diluted solution, sodium ferric gluconate complex should be infused intravenously over a period of 1 hour.[5]
• Slow Intravenous Injection (Undiluted - Adults Only): Alternatively, for adult patients, the 125 mg (10 mL) dose can be administered undiluted as a slow intravenous injection. The rate of this slow IV injection must not exceed 12.5 mg of elemental iron per minute. This translates to administering 1 mL of the undiluted product (12.5 mg/mL) per minute, meaning a 125 mg dose would take at least 10 minutes to administer.[5]
• Compatibility: Sodium ferric gluconate complex should not be mixed with other medications in the same infusion bag or syringe, nor should it be added to parenteral nutrition solutions for co-administration. Its compatibility has been primarily established with 0.9% sodium chloride as the infusion vehicle.[9]
• Visual Inspection: Before administration, the vial containing sodium ferric gluconate complex and any prepared dilutions should be visually inspected for particulate matter and discoloration. The product solution has a characteristic deep red color.[9]
• Stability After Dilution: If the product is diluted in 0.9% sodium chloride for infusion, the prepared solution should be used immediately to ensure stability and sterility.[9]

The provision for either a 1-hour diluted infusion or a more rapid (minimum 10-minute) slow undiluted IV injection for adult patients offers a degree of operational flexibility, which can be beneficial in busy hemodialysis units. The undiluted option reduces preparation time and the volume of fluid administered, which may be advantageous for fluid-restricted patients. However, the faster administration associated with the undiluted injection necessitates extremely careful control of the injection rate. Rapid administration of intravenous iron preparations is known to increase the risk of acute adverse events, particularly hypotension, which is a recognized risk with sodium ferric gluconate complex.[9] Therefore, while convenient, the slow IV push method places a higher demand on the healthcare professional to meticulously adhere to the maximum recommended rate to prevent such rate-related reactions. The diluted infusion over 1 hour is generally considered a safer, more controlled method for delivering the dose.

The explicit dose limitation of 125 mg per session, with clear warnings against exceeding this due to an increased risk of adverse events, is a defining safety parameter for sodium ferric gluconate complex.[7] This distinguishes it from some other intravenous iron products. For example, certain formulations of low molecular weight iron dextran historically allowed for total dose infusion (TDI), and newer agents like ferric carboxymaltose and ferric derisomaltose permit the administration of much larger single doses (e.g., 750 mg or 1000 mg, respectively).[7] The 125 mg per session limit for sodium ferric gluconate complex means that achieving a typical 1-gram iron repletion course requires multiple (typically eight) separate administrations.[9] This fractionated dosing schedule impacts patient convenience and healthcare resource utilization (e.g., staff time, supplies for multiple infusions). However, this approach may contribute to its overall safety profile by avoiding the acute physiological stress and potential for toxicity associated with a very large single bolus of iron, potentially reducing the risk or severity of certain types of adverse reactions.

Table 3: Recommended Dosing and Administration for Sodium Ferric Gluconate Complex (FDA-Approved Indication)

Patient Population	Recommended Dose per Session	Max. Dose per Session	Dilution Instructions (0.9% NaCl)	Administration Method & Rate	Typical Cumulative Repletion Dose	Reference(s)
Adult CKD-HD with Epoetin	125 mg elemental iron (10 mL of 12.5 mg/mL solution)	125 mg	Dilute in 100 mL	1. IV infusion over 1 hour (diluted)<br>2. Slow IV injection up to 12.5 mg/min (undiluted)	1.0 gram (over 8 sessions)	5
Pediatric CKD-HD with Epoetin (Age ≥6 yrs)	1.5 mg/kg elemental iron (0.12 mL/kg of 12.5 mg/mL solution)	125 mg	Dilute in 25 mL	IV infusion over 1 hour (diluted)	Variable based on need	5

VII. Clinical Efficacy Summary

A. Impact on Hematological Parameters

The primary therapeutic goal of sodium ferric gluconate complex administration is the correction of iron deficiency anemia and the repletion of body iron stores. Clinical studies have consistently demonstrated its efficacy in improving key hematological parameters. Following a course of treatment, patients typically exhibit increases in hemoglobin concentration, hematocrit levels, serum ferritin (an indicator of iron stores), and transferrin saturation (TSAT, a measure of iron available for erythropoiesis).[9] The ultimate aim is to achieve and maintain hemoglobin levels within the target range recommended for CKD patients and to ensure adequate iron stores to support ongoing erythropoiesis, particularly when stimulated by ESA therapy.

B. Key Findings from Clinical Studies (e.g., Nulecit® FDA Label)

The FDA-approved product labeling for Nulecit™ (sodium ferric gluconate complex in sucrose injection) includes data from several key clinical studies that established its efficacy in the indicated patient population.[9]

• Study A (Adults, Randomized, Open-Label, Three-Center Study):
• This study assessed the safety and efficacy of two cumulative doses of Nulecit™ (500 mg vs. 1000 mg of elemental iron, administered in eight divided doses during sequential dialysis sessions) in iron-deficient hemodialysis patients. It included both a dose-response concurrent control and a historical control group receiving oral iron.
• Eligibility: Chronic hemodialysis patients with hemoglobin <10 g/dL (or hematocrit ≤32%) and either serum ferritin <100 ng/mL or TSAT <18%.
• Baseline Iron Status: Mean baseline hemoglobin was approximately 9.8 g/dL. Baseline serum ferritin levels were relatively low in the Nulecit™ groups (106 ng/mL for low-dose, 88 ng/mL for high-dose) compared to a much higher baseline in the historical oral iron group (606 ng/mL, suggesting these historical controls might have had different underlying iron status or inflammatory conditions). Baseline TSAT was 20% (low-dose Nulecit™), 16% (high-dose Nulecit™), and 14% (historical oral iron).
• Efficacy Results: The high-dose Nulecit™ group (1000 mg cumulative) achieved significantly greater increases in hemoglobin (mean change +1.13 g/dL) and hematocrit (mean change +3.16%) from baseline to Day 40 compared to both the low-dose Nulecit™ group (500 mg cumulative; Hb change +0.60 g/dL, Hct change +1.59%) and the historical oral iron control group (Hb change +0.16 g/dL, Hct change +0.40%). The low-dose Nulecit™ group did not show significantly greater increases than the oral iron group.
• Study B (Adults, Single-Center, Non-Randomized, Open-Label, Historically Controlled Study):
• This study evaluated variable, cumulative doses of Nulecit™ in iron-deficient hemodialysis patients, with efficacy assessed by the change in hemoglobin from baseline to Day 50.
• Baseline Iron Status: Mean baseline hemoglobin was 9.1 g/dL for the Nulecit™-treated group. Serum ferritin was 77 ng/mL for the Nulecit™ group versus 606 ng/mL for the historical oral iron control group.
• Efficacy Results: The Nulecit™-treated group achieved a significant increase in hemoglobin (mean change +1.30 g/dL) and hematocrit (mean change +3.68%) from baseline. These increases were significantly greater than those observed in the historical oral iron control group.
• Study C (Pediatric Patients, Multicenter, Randomized, Open-Label Study):
• This study assessed two dose regimens of Nulecit™ (1.5 mg/kg or 3.0 mg/kg of elemental iron, maximum 125 mg/dose) in 66 iron-deficient pediatric hemodialysis patients (ages 6 to 15 years) receiving stable erythropoietin therapy. Doses were administered over eight sequential hemodialysis sessions.
• Primary Endpoint: Change in hemoglobin concentration from baseline to 2 weeks after the last Nulecit™ administration.
• Efficacy Results: Both pediatric dose groups demonstrated statistically significant increases in hemoglobin concentrations from baseline. The 1.5 mg/kg dose group had a mean hemoglobin increase of +1.48 g/dL, and the 3.0 mg/kg dose group had a mean increase of +1.30 g/dL. There was no statistically significant difference in hemoglobin change between the two dose groups. Furthermore, statistically significant improvements from baseline were also observed in hematocrit, TSAT, serum ferritin, and reticulocyte hemoglobin concentrations in both groups. The increased hemoglobin concentrations were maintained at the 4-week post-infusion follow-up in both dose groups.

The clinical trial data consistently demonstrate that intravenous sodium ferric gluconate complex is more effective than oral iron supplementation (as represented by historical controls) in elevating hemoglobin levels in the targeted CKD-HD population receiving epoetin. This superior efficacy is particularly crucial given the well-documented limitations of oral iron therapy in these patients, which include poor gastrointestinal absorption (often exacerbated by uremia, concomitant medications like phosphate binders, and inflammation-induced hepcidin elevation), high incidence of gastrointestinal intolerance, and the substantial iron demands created by ESA therapy and ongoing blood losses during dialysis. The data provide a clear pharmacological rationale for preferring IV iron, such as sodium ferric gluconate complex, over oral iron to achieve and maintain therapeutic targets for anemia management in this specific clinical setting.

In the pediatric CKD-HD population, the finding that a 1.5 mg/kg dose of sodium ferric gluconate complex appears to be as effective as a 3.0 mg/kg dose in increasing hemoglobin levels is noteworthy. Both regimens produced statistically significant and clinically meaningful improvements. This observation suggests that the lower 1.5 mg/kg dose might be the preferred regimen to minimize overall drug exposure and potentially reduce the risk of dose-related adverse effects, provided it consistently achieves therapeutic goals. However, this must be balanced with adverse event data from Study C, which indicated that the higher dose (3.0 mg/kg) group experienced a greater incidence of certain adverse events such as hypotension, tachycardia, fever, headache, abdominal pain, nausea, and vomiting.[9] This combined efficacy and safety profile would generally support the use of the lowest effective dose, aligning with the 1.5 mg/kg regimen for pediatric patients.

Table 4: Summary of Key Clinical Trial Efficacy Data for Sodium Ferric Gluconate Complex (from Nulecit® Label)

Study ID	Patient Population	Nulecit® Dose Regimen	Control Group	Baseline Hb (mean, g/dL)	Baseline Ferritin (mean, ng/mL)	Baseline TSAT (mean, %)	Primary Efficacy Endpoint (Change from Baseline)	Key Results (Mean Change from Baseline)	Reference(s)
Study A	Adults, CKD-HD, IDA	High Dose: 125 mg x 8 (1000 mg total)	Low Dose: 62.5 mg x 8 (500 mg total); Historical Oral Iron	~9.8	High: 88; Low: 106	High: 16; Low: 20	Hb & Hct at Day 40	High Dose: Hb +1.13 g/dL, Hct +3.16%<br>Low Dose: Hb +0.60 g/dL, Hct +1.59%<br>Oral Iron: Hb +0.16 g/dL, Hct +0.40% (High dose vs. Low dose & Oral Iron, p<0.05 for Hb & Hct)	9
Study B	Adults, CKD-HD, IDA	Variable cumulative doses (mean 14 doses of 62.5/125 mg)	Historical Oral Iron	9.1	77	N/A	Hb & Hct at Day 50	Nulecit®: Hb +1.30 g/dL, Hct +3.68% (p<0.01 vs. baseline & vs. Oral Iron)<br>Oral Iron: No significant change	9
Study C	Pediatrics (6-15 yrs), CKD-HD, IDA, Stable Epoetin	1.5 mg/kg/dose x 8 sessions<br>3.0 mg/kg/dose x 8 sessions	(Internal dose comparison)	~9.5-9.6	~96-113	~16-17	Hb at 2 wks post-last dose	1.5 mg/kg: Hb +1.48 g/dL<br>3.0 mg/kg: Hb +1.30 g/dL<br>(Both p<0.001 vs. baseline; No significant difference between doses).<br>Significant improvements in Hct, TSAT, Ferritin, Retic Hb also seen.	9

N/A: Not Available in cited snippets for that specific parameter in that group.

VIII. Safety and Tolerability Profile

A. Contraindications

Sodium ferric gluconate complex is contraindicated in patients with a known hypersensitivity to the active drug substance (sodium ferric gluconate) or to any of its inactive components, which may include sucrose and, in many formulations, benzyl alcohol.[4] Given the potential for cross-reactivity, European Medicines Agency (EMA) guidelines also advise contraindication in patients who have experienced serious hypersensitivity reactions to other parenteral iron products.[8] Furthermore, sodium ferric gluconate complex should not be administered to patients with evidence of iron overload, such as those with hemochromatosis or other iron storage disorders.[9]

B. Warnings and Precautions

Several important warnings and precautions are associated with the use of sodium ferric gluconate complex:

1. Hypersensitivity and Anaphylactic Reactions: Serious, occasionally life-threatening, and even fatal anaphylactic-type hypersensitivity reactions have been reported in patients receiving sodium ferric gluconate complex, particularly during post-marketing surveillance.5 Clinical presentations of these reactions can include shock, clinically significant hypotension, loss of consciousness, or cardiovascular collapse. Due to this risk, patients must be closely monitored for signs and symptoms of hypersensitivity during the administration of each dose and for at least 30 minutes following the completion of the infusion or injection. It is imperative that sodium ferric gluconate complex is administered only in settings where personnel trained to manage anaphylaxis and other severe hypersensitivity reactions, as well as appropriate therapies (e.g., epinephrine, antihistamines, corticosteroids, IV fluids, and resuscitation equipment), are immediately available.6 The EMA has stated that the practice of administering a small "test dose" is no longer recommended, as it has not been found to be a reliable predictor of a patient's reaction to the full therapeutic dose; caution is warranted with every dose, even if previous administrations have been well tolerated.8 The risk of hypersensitivity reactions may be increased in patients with a history of known allergies (especially drug allergies), active immune or inflammatory conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus), or a history of severe asthma, eczema, or other atopic allergies.8
2. Hypotension: Sodium ferric gluconate complex administration may cause clinically significant hypotension. These hypotensive episodes can be associated with symptoms such as lightheadedness, malaise, fatigue, weakness, or, in some cases, severe pain in the chest, back, flanks, or groin.2 Such reactions are often not directly associated with other signs of hypersensitivity and typically resolve within one to two hours. Patients should be monitored for signs and symptoms of hypotension during and following each dose. It is also noted that the administration of IV iron may augment the hypotensive effects sometimes experienced by patients during hemodialysis procedures.9
3. Iron Overload: Regular monitoring of hematologic responses, including hemoglobin, serum ferritin, and transferrin saturation (TSAT), is essential during therapy with sodium ferric gluconate complex to guide dosing and to avoid iatrogenic iron overload.5 The drug should not be administered to patients who already have evidence of iron overload. Excessive iron accumulation can lead to hemosiderosis and potential organ damage. Clinicians should be cautious when interpreting serum iron levels within 24 hours of administration and serum ferritin levels within one week of administration, as these may be transiently and non-specifically elevated, respectively, not accurately reflecting true iron status.9
4. Benzyl Alcohol Toxicity: Formulations of sodium ferric gluconate complex that contain benzyl alcohol as a preservative (e.g., Ferrlecit®, Nulecit™) pose a risk of benzyl alcohol toxicity, particularly to premature infants, low-birth-weight infants, and neonates. Benzyl alcohol has been associated with a fatal "gasping syndrome" in this population. Therefore, such formulations are not recommended for use in neonates.1 Caution is also advised when considering use in pregnant or lactating women due to potential fetal or infant exposure.

C. Adverse Reactions (Common, Serious, Post-Marketing)

The safety profile of sodium ferric gluconate complex has been evaluated in clinical trials and through post-marketing surveillance.

• Common Adverse Reactions in Adults (≥10% incidence reported for Ferrlecit® in product labeling): Nausea, vomiting and/or diarrhea, injection site reactions (such as pain, inflammation, or extravasation), hypotension, cramps (muscle or abdominal), hypertension, dizziness, dyspnea, chest pain, leg cramps, and generalized pain.[2] Data from the Nulecit® label (Studies A & B) reported the following common events: injection site reaction (33%), nausea, vomiting and/or diarrhea (35%), cramps (25%), hypotension (29%), hypertension (13%), dizziness (13%), dyspnea (11%), abnormal erythrocytes (11%), chest pain (10%), pain (10%), and leg cramps (10%).[9]
• Common Adverse Reactions in Pediatric Patients (≥5% incidence reported in Nulecit® label Study C): Hypotension (35%), headache (24%), hypertension (23%), tachycardia (17%), vomiting (11%), fever (9%), nausea (9%), abdominal pain (9%), pharyngitis (9%), diarrhea (8%), infection (8%), rhinitis (6%), and thrombosis (6%).[2] The higher dose group (3.0 mg/kg) in the pediatric study experienced a greater incidence of hypotension, tachycardia, fever, headache, abdominal pain, nausea, vomiting, pharyngitis, and rhinitis compared to the 1.5 mg/kg group.[9]
• Serious Adverse Reactions: The most significant serious adverse reactions are life-threatening hypersensitivity/anaphylactic reactions and severe hypotension, as detailed in the Warnings and Precautions section.
• Post-Marketing Reports: Additional adverse reactions identified during post-marketing use include dysgeusia (altered taste), hypoesthesia (reduced sense of touch or sensation), loss of consciousness, convulsion, skin discoloration, pallor, phlebitis, and shock.[9]

The paramount safety concern associated with sodium ferric gluconate complex, as with all intravenous iron preparations, is the risk of hypersensitivity and anaphylactic reactions. This risk necessitates stringent administration protocols, including the immediate availability of resuscitation equipment and trained personnel, and diligent post-infusion monitoring of the patient. This risk persists with each dose, irrespective of prior tolerance, and the unreliability of test doses (as noted by the EMA) means that vigilance cannot be relaxed.[8] This implies a higher level of care and resource allocation compared to orally administered medications.

Hypotension is another frequently reported adverse event that can occur independently of, or as part of, a hypersensitivity reaction. It may also be exacerbated by the hemodialysis procedure itself, to which CKD patients are already susceptible. This underscores the need for careful patient monitoring, particularly blood pressure, during and after the infusion, and may require adjustments to the infusion rate or supportive measures if significant hypotension develops.

A toxicological finding noted in the Nulecit® product label is a clastogenic effect (i.e., causing chromosomal damage) observed in an in vitro chromosomal aberration assay using Chinese hamster ovary (CHO) cells.[9] However, the drug was not found to be mutagenic in the Ames test or the in vivo rat micronucleus test. It is important to recognize that in vitro clastogenicity does not always translate to in vivo genotoxicity or carcinogenicity in humans, and long-term carcinogenicity studies with sodium ferric gluconate complex have not been performed. While not a direct contraindication for use, this preclinical safety finding is an element of the drug's overall toxicological profile that warrants awareness.

Table 5: Common and Serious Adverse Reactions Associated with Sodium Ferric Gluconate Complex

System Organ Class	Common Adverse Reactions (Adults)	Common Adverse Reactions (Pediatrics, ≥6 yrs)	Serious Adverse Reactions (All Populations)	Key Post-Marketing Findings	Reference(s)
General Disorders and Administration Site Conditions	Injection site reaction (pain, inflammation) (33%), Pain (10%), Asthenia (7%), Headache (7%), Fatigue (6%), Fever (5%), Malaise, Chills, Rigors, Flu-like syndrome	Headache (24%), Fever (9%), Infection (8%)	Anaphylactic/Anaphylactoid reactions, Shock, Collapse	Loss of consciousness, Skin discoloration, Pallor, Phlebitis	2
Gastrointestinal Disorders	Nausea, Vomiting and/or Diarrhea (35%), Abdominal pain (6%), Anorexia, Dyspepsia	Vomiting (11%), Nausea (9%), Abdominal pain (9%), Diarrhea (8%)	-	Dysgeusia	2
Musculoskeletal and Connective Tissue Disorders	Cramps (25%), Leg cramps (10%), Myalgia, Arthralgia	-	Rhabdomyolysis (rare, class effect for IV iron if severe reaction/overload)	-	2
Nervous System Disorders	Dizziness (13%), Paresthesias (6%)	Headache (24%)	Convulsions	Hypoesthesia, Convulsion	2
Respiratory, Thoracic and Mediastinal Disorders	Dyspnea (11%), Coughing (6%), Upper respiratory infections (6%), Rhinitis	Pharyngitis (9%), Rhinitis (6%)	Bronchospasm (as part of hypersensitivity)	-	2
Vascular Disorders	Hypotension (29%), Hypertension (13%), Syncope (6%), Tachycardia (5%)	Hypotension (35%), Hypertension (23%), Tachycardia (17%)	Severe Hypotension, Shock	-	2
Skin and Subcutaneous Tissue Disorders	Pruritus (6%), Rash, Increased sweating	-	Urticaria, Angioedema (as part of hypersensitivity)	Skin discoloration	6
Blood and Lymphatic System Disorders	Abnormal erythrocytes (11%), Anemia	Thrombosis (6%)	-	-	9
Metabolism and Nutrition Disorders	Hyperkalemia (6%), Generalized edema (5%), Hypoglycemia	-	Iron Overload (with excessive dosing/duration)	-	9

Incidences for adult common AEs are primarily from Nulecit® label, Studies A&B. Pediatric common AEs from Nulecit® label, Study C.

D. Drug Interactions

The provided product labeling for sodium ferric gluconate complex (e.g., Nulecit™, Ferrlecit®) does not contain extensive lists of specific drug-drug interaction studies for this compound.[6] The primary cautionary advice regarding interactions is practical: sodium ferric gluconate complex should not be mixed with other medications in the same intravenous infusion bag or syringe, as compatibility and stability with other drugs have not been thoroughly evaluated.[9]

A general principle with parenteral iron therapy is that it should not be administered concomitantly with oral iron preparations. The rationale is that parenteral iron administration leads to saturation of iron-binding proteins and high circulating iron levels, which can impair the absorption of oral iron and may increase the risk of gastrointestinal side effects from unabsorbed oral iron. Additionally, concurrent use makes it difficult to assess the efficacy and iron status accurately.

While not specific to sodium ferric gluconate, ACE inhibitors have been anecdotally associated with an increased incidence of hypersensitivity-like reactions when co-administered with some IV iron products, although the Nulecit® label noted that incidences of drug intolerance and suspected allergic events were 1.6% in patients with concomitant ACE inhibitor use versus 0.7% in those without, in a single-dose post-marketing study.[9] This suggests a possible, though not definitively established, interaction that warrants awareness.

Patients should always inform their healthcare providers of all medications, including over-the-counter drugs and herbal supplements, they are taking to allow for a comprehensive assessment of potential interactions.

E. Use in Specific Populations

• Pregnancy: The use of sodium ferric gluconate complex during pregnancy requires careful consideration of potential risks and benefits. Parenteral iron administration, in general, carries a risk of maternal hypersensitivity reactions, which could have serious consequences for the fetus, such as fetal bradycardia.6 Product labeling advises that the drug should be used during pregnancy only if clearly needed. A significant concern for many formulations of sodium ferric gluconate complex (e.g., Ferrlecit®, Nulecit™) is the presence of benzyl alcohol as a preservative.1 Benzyl alcohol can cross the placenta, and there are concerns about its potential effects on the developing fetus. The EMA specifically advises against the use of intravenous iron medicines during pregnancy unless clearly necessary, and if used, treatment should ideally be confined to the second or third trimester, provided the benefits are judged to outweigh the potential serious risks to the fetus (e.g., anoxia, fetal distress resulting from maternal hypersensitivity).8 Available data from postmarketing reports with Ferrlecit® use in pregnancy are deemed insufficient to definitively assess the risk of major birth defects and miscarriage.6 Animal reproduction studies with sodium ferric gluconate complex did not show teratogenicity in mice or rats at doses up to 1.3 and 3.24 times the recommended human dose on a body surface area basis, respectively.9
• Lactation: It is not definitively known whether sodium ferric gluconate complex or its metabolites are excreted in human milk. However, a key concern is the presence of benzyl alcohol in many formulations. Benzyl alcohol may be excreted into breast milk and subsequently absorbed by the nursing infant, potentially leading to adverse effects.1 Therefore, product labeling often states that breastfeeding is not recommended while receiving these formulations 6, or that caution should be exercised. LactMed suggests that an alternative intravenous iron drug with more published safety data in lactation or one that is free of benzyl alcohol might be preferred.1
• Pediatric Use: The safety and effectiveness of sodium ferric gluconate complex have been established for pediatric patients aged 6 years and older with chronic kidney disease receiving hemodialysis and supplemental epoetin therapy, based on clinical trial data (e.g., Study C in Nulecit® label).5 Dosing is weight-based (1.5 mg/kg) up to a maximum of 125 mg per dose. Safety and effectiveness have not been established in pediatric patients younger than 6 years of age. Formulations containing benzyl alcohol should not be used in neonates due to the risk of "gasping syndrome" and other toxicities.6
• Geriatric Use: Clinical studies of sodium ferric gluconate complex have included subjects aged 65 years and over. While no overall differences in safety or efficacy were identified specifically for this age group compared to younger adults, dose selection in geriatric patients should be cautious. This typically involves starting at the lower end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapies common in the elderly population.9 Renal function should be a key consideration given the CKD context.

F. Management of Overdosage

Acute iron overdosage with sodium ferric gluconate complex can lead to iatrogenic hemosiderosis due to the body's limited capacity to excrete excess iron.[9] Serum iron levels exceeding 300 mcg/dL may be indicative of iron poisoning, although this threshold can vary. Symptoms of acute iron toxicity can include abdominal pain, nausea, vomiting, diarrhea, pallor or cyanosis, lassitude, drowsiness, hyperventilation due to metabolic acidosis, and in severe cases, cardiovascular collapse.[9]

It is important to exercise caution when interpreting serum iron levels measured within 24 hours after administration of sodium ferric gluconate complex, as some laboratory assays may overestimate the biologically available iron due to interference from the circulating iron complex. Similarly, serum ferritin levels may show a non-specific rise within one week of IV iron administration and may not accurately reflect true iron stores during this immediate post-dose period.[9]

The sodium ferric gluconate iron complex is not dialyzable, meaning hemodialysis is not an effective method for removing the drug in cases of overdose.[9] Management of overdosage is primarily supportive. If iron poisoning is suspected, treatment may involve measures to support cardiovascular and respiratory function, correct acidosis, and, in severe cases of iron overload, chelation therapy with an agent like deferoxamine might be considered, although specific guidance for chelation following sodium ferric gluconate complex overdose is not detailed in the provided snippets.

Animal studies have established lethal doses (LD₅₀): 125 mg/kg in mice, 78.8 mg/kg in rats, 62.5 mg/kg in rabbits, and 250 mg/kg in dogs. Symptoms of acute toxicity in these animal models included decreased activity, staggering, ataxia, increased respiratory rate, tremor, and convulsions.[9] Post-marketing reports suggest that individual human doses exceeding 125 mg may be associated with a higher incidence and/or severity of adverse events such as hypotension, nausea, vomiting, abdominal pain, diarrhea, dizziness, dyspnea, urticaria, chest pain, and paresthesia.[9]

IX. Regulatory Status and Product Availability

A. Global Regulatory Approvals

• United States (FDA): Sodium ferric gluconate complex is an approved drug product in the United States. The brand Ferrlecit® received its FDA approval in February 1999.[7] It is indicated for the treatment of iron deficiency anemia in adult and pediatric patients (aged 6 years and older) with chronic kidney disease (CKD) who are undergoing hemodialysis and are also receiving supplemental epoetin therapy.[2]
• European Union (EMA): Sodium ferric gluconate complex is authorized in EU Member States through national approval procedures rather than a centralized EMA marketing authorization.[8] All intravenous iron preparations, including sodium ferric gluconate, were subject to an Article 31 referral review by the EMA's Committee for Medicinal Products for Human Use (CHMP). This review, which concluded in June 2013 and was subsequently endorsed by the European Commission in September 2013, confirmed a positive benefit-risk balance for these products, provided that harmonized measures were implemented across the EU to manage and minimize the risk of allergic reactions.[8] In the European context, IV iron products like sodium ferric gluconate are generally used when oral iron supplements are ineffective or cannot be tolerated, particularly in patients undergoing dialysis for kidney failure, in the peri-operative setting, or in patients with malabsorption syndromes.[8]

The EMA's Article 31 referral for all IV iron products, including sodium ferric gluconate complex, was a significant regulatory action that underscored a class-wide concern regarding the risk of hypersensitivity reactions. This comprehensive review led to the implementation of harmonized risk minimization strategies across all EU member states. These strategies include standardized warnings, contraindications, and recommendations for administration, such as ensuring availability of resuscitation facilities, close patient monitoring during and after infusion, and updated advice on managing patients with pre-existing allergic or inflammatory conditions. This EU-wide action reflects a concerted effort to enhance the safe use of this important class of medicines.

B. Brand Names and Manufacturers

Sodium ferric gluconate complex is available under several brand names and as a generic product from various manufacturers:

• Ferrlecit®: This brand has been associated with Sanofi Pasteur (as listed by McKesson [12]) and Sanofi-Aventis US.[7] Product information on DailyMed and GoodRx also refers to Ferrlecit®.[2]
• Nulecit™: The product labeling for Nulecit™ indicates distribution by entities such as Watson Pharma, Inc., with manufacturing by companies like Laboratorios Grifols, S.A. Spain, though specific manufacturing arrangements can vary over time and by region.[9]
• Sodium Ferric Gluconate Complex (Generic): Generic versions are also available. For example, Hikma Pharmaceuticals is listed as a manufacturer by McGuff Medical Products.[11]

The availability of multiple brands and generic versions of sodium ferric gluconate complex indicates a well-established market presence for this IV iron preparation. However, it is crucial for clinicians and pharmacists to be aware that while the active pharmaceutical ingredient (the iron complex) is the same, formulations may differ in their excipients. A key example is the presence or absence of benzyl alcohol, which, as previously discussed, has significant implications for use in specific patient populations like neonates, pregnant women, and breastfeeding mothers.[1] Therefore, when prescribing or administering sodium ferric gluconate complex, it is not sufficient to refer to the drug by its generic name alone; the specific product label for the brand or generic being used must be consulted to ascertain the complete list of excipients and any associated warnings or contraindications. This ensures the selection of the most appropriate product for the individual patient's circumstances.

X. Discussion and Expert Recommendations

A. Key Considerations for Clinical Use

Sodium ferric gluconate complex holds an established position in the management of iron deficiency anemia, particularly within its FDA-approved niche: adult and pediatric (≥6 years) patients with chronic kidney disease undergoing hemodialysis who are also receiving supplemental epoetin therapy. Its efficacy in raising hemoglobin and replenishing iron stores in this challenging patient population, where oral iron is often inadequate, is supported by clinical trial data.[9]

However, its use must be carefully balanced against significant safety considerations. The risk of hypersensitivity reactions, including rare but potentially fatal anaphylaxis, is paramount and necessitates administration in settings equipped for emergency management and by personnel trained to handle such events.[6] Hypotension is another common adverse event that requires vigilant patient monitoring during and after infusion, especially given that hemodialysis patients may already be predisposed to hemodynamic instability.[6]

Adherence to the approved indication is crucial, particularly the concurrency of epoetin therapy, as the drug's primary role in this context is to fuel ESA-driven erythropoiesis. Off-label use, while sometimes clinically justified in other IDA scenarios where IV iron is necessary (e.g., severe oral iron intolerance or malabsorption), should be approached with caution and guided by established clinical guidelines or payer-defined criteria.[4]

The dosing limitation of 125 mg per session for sodium ferric gluconate complex means that full iron repletion (e.g., a 1-gram course) requires multiple administrations, typically over eight dialysis sessions.[9] This contrasts with some newer IV iron formulations like ferric carboxymaltose or ferric derisomaltose, which allow for larger single doses and thus fewer administrations to achieve the same cumulative iron dose.[7] This difference has implications for patient convenience, healthcare resource utilization, and potentially overall cost-effectiveness, which must be weighed against the specific safety and efficacy profile of each agent for an individual patient.

B. Monitoring Recommendations

Effective and safe use of sodium ferric gluconate complex requires diligent patient monitoring:

1. Hematologic Parameters: Regular monitoring of hemoglobin, hematocrit, serum ferritin, and transferrin saturation (TSAT) is essential to assess therapeutic response, guide ongoing dosing (including transition to maintenance therapy), and prevent iron overload. Baseline measurements should be obtained, and these parameters should be re-evaluated periodically throughout the treatment course and during maintenance therapy.[5] It is important to be aware that serum iron levels within 24 hours post-dose and serum ferritin levels within one week post-dose may be misleading.[9]
2. Vital Signs: Blood pressure and heart rate should be monitored before, during, and after the infusion, particularly during the initial administrations and if the patient has a history of cardiovascular instability or previous reactions.[5]
3. Hypersensitivity Reactions: Patients must be closely observed for any signs or symptoms of hypersensitivity (e.g., rash, urticaria, pruritus, angioedema, dyspnea, wheezing, stridor, hypotension, syncope, chest pain, back pain) during the entire infusion and for at least 30 minutes after its completion. This is critical for every dose administered.[6]
4. Injection Site: Monitor the IV access site for signs of pain, swelling, irritation, or extravasation.
5. Clinical Symptoms: Patients should be instructed to report any unusual symptoms, such as severe pain, dizziness, malaise, or other discomfort, during or after the infusion.

C. Comparison with other IV Iron Formulations

Sodium ferric gluconate complex occupies an intermediate position in the historical and current landscape of intravenous iron preparations. Compared to older, high-molecular-weight iron dextran formulations, sodium ferric gluconate (along with iron sucrose) is generally considered to have a lower risk of severe anaphylactic reactions, primarily because it lacks the dextran moiety which was implicated in many of these events.[7] This improved safety profile was a significant advancement.

However, when compared to some of the newer IV iron formulations, such as ferric carboxymaltose (FCM) and ferric derisomaltose (FDI, also known as iron isomaltoside), sodium ferric gluconate complex has a more restrictive dosing regimen. FCM and FDI allow for the administration of much larger single doses of iron (e.g., 750-1000 mg in a single session), enabling complete iron repletion in one or two visits.[7] In contrast, the typical 125 mg dose limit per session for sodium ferric gluconate necessitates multiple administrations (e.g., eight sessions for a 1g course).[7] This can impact patient convenience and overall treatment burden.

The decision to use sodium ferric gluconate complex versus other IV iron preparations involves a multifaceted assessment by the clinician. Factors influencing this choice include: the specific FDA or EMA approved indications for each product; the patient's clinical status and urgency of iron repletion; the required frequency of administration and its impact on patient adherence and healthcare logistics; the patient's history of allergies or previous reactions to other iron products; the presence of specific risk factors (e.g., pregnancy, neonatal status requiring a benzyl alcohol-free formulation); and institutional formularies or payer coverage policies. The historical context of IV iron development shows a continuous evolution: from the higher-risk first-generation iron dextrans to safer second-generation complexes like sodium ferric gluconate and iron sucrose, and now towards third-generation agents that aim to combine robust efficacy and safety with improved patient convenience through less frequent, higher-dose administrations. Sodium ferric gluconate complex represents an important and established therapeutic option within this evolving spectrum, particularly valued for its long history of use and defined role in the CKD-HD population.

XI. Conclusion

Sodium ferric gluconate complex is a well-established parenteral iron replacement therapy with a specific and important role in the management of iron deficiency anemia in adult and pediatric patients (aged 6 years and older) with chronic kidney disease who are undergoing hemodialysis and receiving concurrent epoetin therapy. Its chemical structure as a stable macromolecular complex of ferric iron, sucrose, and gluconate allows for intravenous administration and controlled release of iron via the reticuloendothelial system, thereby replenishing iron stores and supporting epoetin-stimulated erythropoiesis.

Clinical studies have demonstrated its efficacy in improving hemoglobin levels and other iron indices, proving superior to oral iron in this challenging patient population. However, its administration is associated with important safety considerations, most notably the risk of serious hypersensitivity reactions, including anaphylaxis, and the potential for hypotension. These risks necessitate administration in appropriate clinical settings with immediate access to emergency treatment and vigilant patient monitoring during and after each dose. The presence of benzyl alcohol in many formulations also requires careful consideration in specific populations such as neonates, pregnant women, and nursing mothers.

The dosing regimen, typically 125 mg of elemental iron per session, requires multiple administrations for full iron repletion, which contrasts with some newer IV iron agents that allow for larger, less frequent dosing. The choice of sodium ferric gluconate complex should be guided by its approved indications, the individual patient's clinical profile, risk factors, and a thorough assessment of the benefits versus potential risks.

In summary, sodium ferric gluconate complex remains a valuable therapeutic tool for a specific group of anemic CKD patients. Its effective use hinges on a comprehensive understanding of its pharmacology, strict adherence to administration and safety protocols, and careful patient selection and monitoring.

Works cited

1. Sodium Ferric Gluconate Complex | C66H121Fe2NaO65 | CID 76968835 - PubChem, accessed May 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/76968835
2. Sodium ferric gluconate complex - Wikipedia, accessed May 24, 2025, https://en.wikipedia.org/wiki/Sodium_ferric_gluconate_complex
3. Sodium ferric gluconate complex: Uses, Interactions, Mechanism of ..., accessed May 24, 2025, https://go.drugbank.com/drugs/DB09517
4. Clinical Policy: Ferric Gluconate (Ferrlecit) - Louisiana Department of Health, accessed May 24, 2025, https://ldh.la.gov/assets/medicaid/MCPP/3.17.21/LA.PHAR.166FerricGluconateFerrlecit.pdf
5. Ferrlecit: Uses, Side Effects, Dosage & More - GoodRx, accessed May 24, 2025, https://www.goodrx.com/ferrlecit/what-is
6. FERRLECIT- sodium ferric gluconate complex injection - DailyMed, accessed May 24, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1fe028ff-42ac-4329-b1a5-a9dadfcb79f6
7. www.sabm.org, accessed May 24, 2025, https://www.sabm.org/assets/pdfs/2biii-IV-Iron-Products.pdf
8. Intravenous iron-containing medicinal products - referral | European ..., accessed May 24, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-iron-containing-medicinal-products
9. Nulecit: Package Insert / Prescribing Information - Drugs.com, accessed May 24, 2025, https://www.drugs.com/pro/nulecit.html
10. Ferrlecit (sodium ferric gluconate complex in sucrose injection) - accessdata.fda.gov, accessed May 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020955s010lbl.pdf
11. Sodium Ferric Gluconate Complex (IV Iron) Injection 12.5 mg/mL, Single Dose Vial 5mL, 10/Tray | McGuff, accessed May 24, 2025, https://www.mcguff.com/copy-of-ferrlecit-ferric-gluconate-complex-125mgml-sdv-5ml-10tray
12. Ferrlecit® Sodium Ferric Gluconate / Sucrose 62.5 - McKesson, accessed May 24, 2025, https://mms.mckesson.com/product/769686/Sanofi-Pasteur-00024279210
13. SAFETY DATA SHEET - Medline, accessed May 24, 2025, https://www.medline.com/media/catalog/Docs/MSDS/MSD_SDSD718785.pdf
14. Clinical Policy: Ferric Gluconate (Ferrlecit) - NH Healthy Families, accessed May 24, 2025, https://www.nhhealthyfamilies.com/content/dam/centene/NH%20Healthy%20Families/Medicaid/NHPharmacyPT/Final%20CP.PHAR.166.Ferric%20Gluconate%20(Ferrlecit).12.01.17.pdf
15. Patient and Clinician Group Input - Canada's Drug Agency, accessed May 24, 2025, https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0852%20ferric%20carboxymaltose%20HF%20consolidated%20Patient%20and%20Clinician%20Group%20Input.pdf
16. Ferrlecit (ferric gluconate) dosing, indications, interactions, adverse effects, and more, accessed May 24, 2025, https://reference.medscape.com/drug/ferrlecit-ferric-gluconate-342159
17. Sodium ferric gluconate complex Uses, Side Effects & Warnings - Drugs.com, accessed May 24, 2025, https://www.drugs.com/mtm/sodium-ferric-gluconate-complex.html
18. Label: FERRIC CITRATE tablet, film coated - DailyMed, accessed May 24, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e8396fa-288b-402e-82b0-b1007d1b571f